Patents by Inventor Masaomi Tajimi

Masaomi Tajimi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210179613
    Abstract: The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.
    Type: Application
    Filed: March 2, 2021
    Publication date: June 17, 2021
    Applicant: RaQualia Pharma Inc.
    Inventors: Kaoru SHIMADA, Masaki SUDO, Masaomi TAJIMI, Nobuyuki TAKAHASHI, Kazuhiko NONOMURA
  • Patent number: 11033532
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can more effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: June 15, 2021
    Assignee: HK INNO.N CORPORATION
    Inventors: Ha Jin Lee, Bong Tae Kim, Hyun Kim, Ji Yeon Nam, Jie Eun Park, Geun Seog Song, Shin Young Ryu, Shinichi Koizumi, Nobuyuki Takahashi, Masaomi Tajimi
  • Patent number: 10975070
    Abstract: The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: April 13, 2021
    Assignee: RaQualia Pharma Inc.
    Inventors: Kaoru Shimada, Masaki Sudo, Masaomi Tajimi, Nobuyuki Takahashi, Kazuhiko Nonomura
  • Publication number: 20200069652
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can more effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Application
    Filed: November 7, 2019
    Publication date: March 5, 2020
    Applicants: CJ HEALTHCARE CORPORATION, RaQualia Pharma Inc.
    Inventors: Ha Jin LEE, Bong Tae KIM, Hyun KIM, Ji Yeon NAM, Jie Eun PARK, Geun Seog SONG, Shin Young RYU, Shinichi KOIZUMI, Nobuyuki TAKAHASHI, Masaomi TAJIMI
  • Patent number: 10512635
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can mere effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: December 24, 2019
    Assignees: CJ Healthcare Corporation, RaQualia Pharma Inc.
    Inventors: Ha Jin Lee, Bong Tae Kim, Hyun Kim, Ji Yeon Nam, Jie Eun Park, Geun Seog Song, Shin Young Ryu, Shinichi Koizumi, Nobuyuki Takahashi, Masaomi Tajimi
  • Publication number: 20180338954
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can mere effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Application
    Filed: June 8, 2016
    Publication date: November 29, 2018
    Applicants: CJ HEALTHCARE CORPORATION, RaQualia Pharma Inc.
    Inventors: Ha Jin LEE, Bong Tae KIM, Hyun KIM, Ji Yeon NAM, Jie Eun PARK, Geun Seog SONG, Shin Young RYU, Shinichi KOIZUMI, Nobuyuki TAKAHASHI, Masaomi TAJIMI
  • Publication number: 20120322821
    Abstract: The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.
    Type: Application
    Filed: February 28, 2011
    Publication date: December 20, 2012
    Applicant: RAQUALIA PHARMA INC.
    Inventors: Kaoru Shimada, Masaki Sudo, Masaomi Tajimi, Nobuyuki Takahashi, Kazuhiko Nonomura
  • Patent number: 8173841
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: May 8, 2012
    Assignee: Xention Limited
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Patent number: 8088826
    Abstract: This invention relates to tetrahydro-Naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tethrahydro—Naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontienence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: January 3, 2012
    Assignee: Xention Limited
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Publication number: 20110178088
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 21, 2011
    Applicant: XENTION LIMITED
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Publication number: 20100137361
    Abstract: This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).
    Type: Application
    Filed: February 4, 2010
    Publication date: June 3, 2010
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Axel BOUCHON, Nicole Diedrichs, Achim Hermann, Klemens Lustig, Heinrich Meier, Josef Pernerstorfer, Elke Reissmüller, Muneto Mogi, Hiroshi Fujishima, Masaomi Tajimi, Noriyuki Yamamoto
  • Patent number: 7683076
    Abstract: This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: March 23, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Axel Bouchon, Nicole Diedrichs, Achim Hermann, Klemens Lustig, Heinrich Meier, Josef Pernerstorfer, Elke Reiβmüller, Muneto Mogi, Hiroshi Fujishima, Masaomi Tajimi, Noriyuki Yamamoto
  • Patent number: 7615557
    Abstract: This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q1a, Q2a, Q3a and Q4a are defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q1b, Q2b, Q3b, Q4b, Q5b, R1b, na, ma, Xa and Ra are defined.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: November 10, 2009
    Assignee: Xention Limited
    Inventors: Axel Bouchon, Nicole Diedrichs, Achim Hermann, Klemens Lustig, Heinrich Meier, Josef Pernerstorfer, Elke Reissmuller, Jean De Vry, Muneto Mogi, Klaus Urbahns, Takeshi Yura, Hiroshi Fujishima, Masaomi Tajimi, Noriyuki Yamamoto, Yasuhiro Tsukimi, Hiroaki Yuasa, Jang Gupta, Fumihiko Hayashi
  • Patent number: 7612113
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: November 3, 2009
    Assignee: Xention Limited
    Inventors: Takeshi Yura, Muneto Mogi, Klaus Urbahns, Hiroshi Fujishima, Tsutomu Masuda, Toshiya Moriwaki, Nagahiro Yoshida, Toshio Kokubo, Masahiro Shiroo, Masaomi Tajimi, Yasuhiro Tsukimi, Noriyuki Yamamoto
  • Publication number: 20090209514
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydronaphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Application
    Filed: April 29, 2009
    Publication date: August 20, 2009
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Patent number: 7544716
    Abstract: This invention relates to tetrahydro-naphthalene derivatives of formula (I) in which the variable groups are as defined in the specification and claims, and tautomeric and stereoisomeric forms and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. The compounds, pharmaceutical compositions containing them, and methods of treatment using them are disclosed and claimed.
    Type: Grant
    Filed: November 28, 2003
    Date of Patent: June 9, 2009
    Assignee: Xention Limited
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Publication number: 20080275047
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tethrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontienence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Application
    Filed: April 15, 2008
    Publication date: November 6, 2008
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Patent number: 7423175
    Abstract: This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excellent activity as VR1 antagonist and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: September 9, 2008
    Assignee: Bayer Healthcare AG
    Inventors: Takeshi Yura, Muneto Mogi, Hiroshi Fujishima, Klaus Urbahns, Tsutomu Masuda, Yasuhiro Tsukimi, Masaomi Tajimi, Noriyuki Yamamoto, Nagahiro Yoshida, Toshiya Moriwaki
  • Patent number: 7381840
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I) in which R1 represents hydrogen or C1-6 alkyl, and X represents —N(H)Y1, —(H)—C1-6 alkyleneY1, biphenyl or C1-6 alkyl substituted by biphenyl, and the group Y1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Grant
    Filed: November 28, 2003
    Date of Patent: June 3, 2008
    Assignee: Xention Limited
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Publication number: 20080058377
    Abstract: This invention relates to bicyclic amide, carbamate or urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The bicyclic amide, carbamate or urea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).
    Type: Application
    Filed: October 26, 2004
    Publication date: March 6, 2008
    Applicant: Bayer HealthCare AG
    Inventors: Muneto Mogi, Hiroshi Fujishima, Masaomi Tajimi, Noriyuki Yamamoto, Klaus Urbahns, Fumihiko Hayashi, Yasuhiro Tsukimi, Jang Gupta, Hiroaki Yuasa